2021–2022 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Practitioners
Click here to view the recording with the integrated audio transcript using the password below. external icon
“This content and conclusions are those of the author and presenter and do not necessarily represent the views of, nor should any endorsements be inferred by, the Centers for Disease Control and Prevention. ”
The fully captioned video and edited transcript will be posted within the next few days.
This COCA Call will be held on Friday, March 27, 2020
Influenza remains a serious threat to children due to its potential to cause severe morbidity and mortality. The 2020–2021 influenza season was mild, but it’s not possible to predict how severe the upcoming season may be. Historically, low influenza virus circulation since March 2020, could result in a severe season for young children who may have lower immunity to influenza because they may not have been previously vaccinated or had natural exposure to influenza viruses.
Immunization remains the most effective way to prevent influenza illness, its complications, and death. Influenza immunization in the pediatric population is particularly important during the severe COVID-19 pandemic. Clinicians play a critical role in vaccinating children, their family members and caregivers, and themselves. Additionally, the early use of influenza antiviral medications in children can reduce the duration of symptoms and prevent severe complications of influenza.
During this COCA call, subject matter experts from the American Academy of Pediatrics (AAP) and CDC will discuss strategies primary care providers and medical subspecialists can use to improve, prevent, and control influenza among children this season.
David Shay, MD
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
Flor Munoz, MD, MSc, FAAP
Associate Professor of Pediatrics, Infectious Diseases, and Molecular Virology and Microbiology
Baylor College of Medicine
Due to the high demand we anticipate for this COCA Call, we encourage participants to consider viewing on Facebook. To see the call live, please click on COCA’s Facebook Page.
Thursday, October 7, 2021,
2:00 PM – 3:00 PM ET
US: +1 669 254 5252
or +1 646 828 7666
or +1 551 285 1373
or +1 669 216 1590
International numbersexternal icon
US: +16692545252,,1601173046#,,,,*214351# or +16468287666,,1601173046#,,,,*214351#
Webinar ID: 160 117 3046Add to Calendar
Registration is not required.
Date: Thursday, October 7, 2021
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar begins, please click the link below to join:
Webinar ID: 160 117 3046
Dial-in US: +1 669 254 5252 or +1 646 828 7666 or +1 551 285 1373 or +1 669 216 1590
One-tap mobile: US: +16692545252,,1601173046#,,,,*214351# or +16468287666,,1601173046#,,,,*214351#
International numbers available: https://www.zoomgov.com/u/aczUaOSnLXexternal icon
- Review data from the 2020–2021 U.S. influenza season to inform preparations for the 2021–2022 U.S. influenza season.
- Highlight key recommendations in the AAP influenza policy statement, “Recommendations for Prevention and Control of Influenza in Children, 2021–2022” and in the CDC Advisory Committee on Immunization Practices’ document, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2021–22 Influenza Season.”
- Discuss the importance of vaccinating, testing, and treating influenza during the COVID-19 pandemic.
- Review recommendations about using influenza antiviral in children.
COCA Call Objectives
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
- Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
- Influenza Guidance | AAPexternal icon
- Influenza Resources | Red Book Online | AAPexternal icon
- Preparing for Flu Season | AAPexternal icon
- The American Academy of Pediatrics Recommendations for Prevention and Control of Influenza in Children, 2021-22
To receive continuing education (CE) for WC2922-100721—Clinician Outreach and Communication Activity (COCA) Calls/Webinars—2021–2022 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Practitioners Thursday, October 7, 2021, please visit TCEO and follow these 9 Simple Steps by November 8, 2021.
To receive continuing education (CE) for WD2922-100721—Clinician Outreach and Communication Activity (COCA) Calls/Webinars—2021–2022 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Practitioners Thursday, October 7, 2021, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between November 9, 2021 and November 9, 2023.
CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity provides 1.0 contact hour.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to total 1 Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.
CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is a designated event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-21-230-L04-P and enduring JA4008229-0000-21-231-H04-P
This program has been designated knowledge based.
Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.
CPH: The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1.0 CPH recertification credits for this program.
AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at email@example.com if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.
DISCLOSURE: In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters, except Flor Munoz would like to disclose that she receives a royalty for authoring the Seasonal Influenza in Children chapter in UpToDate and is a member of the Data Safety Monitoring Board (DSMB) – Pfizer, Moderna and a member of the American Academy of Pediatrics (AAP) Committee on Infectious Diseases (COID).
Planners have reviewed content to ensure there is no bias.
The presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.
CDC did not accept commercial support for this continuing education activity
- Physician Assistants
- Health Educators
- Other Clinicians
- Contact Information:firstname.lastname@example.org
- Support/Funding:Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- Method of Participation:You may participate in the educational activity by viewing the program information above.